690 related articles for article (PubMed ID: 20116628)
1. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
2. [Etravirine in first-line therapy].
Garcés PA; Tena EV
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():12-20. PubMed ID: 20116623
[TBL] [Abstract][Full Text] [Related]
3. [Safety and tolerability of etravirine].
Portilla J
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():21-6. PubMed ID: 20116624
[TBL] [Abstract][Full Text] [Related]
4. [Etravirine in highly treatment-experienced patients].
Palter DP; Corbera EF; Tiraboschi JM
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
[TBL] [Abstract][Full Text] [Related]
5. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
6. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
[TBL] [Abstract][Full Text] [Related]
7. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
8. [Etravirine drug interactions].
Pérez VE; Sánchez-Parra C; Serrano Villar S
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():27-31. PubMed ID: 20116625
[TBL] [Abstract][Full Text] [Related]
9. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
10. [Etravirine in special populations].
Santos Gil Ide L
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():40-5. PubMed ID: 20116627
[TBL] [Abstract][Full Text] [Related]
11. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
Floris-Moore MA; Mollan K; Wilkin AM; Johnson MA; Kashuba AD; Wohl DA; Patterson KB; Francis O; Kronk C; Eron JJ
Antivir Ther; 2016; 21(1):55-64. PubMed ID: 26263403
[TBL] [Abstract][Full Text] [Related]
13. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Arazo Garcés P; Omiste Sanvicente T
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
[TBL] [Abstract][Full Text] [Related]
14. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
15. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
Antivir Ther; 2010; 15(6):817-29. PubMed ID: 20834094
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
[TBL] [Abstract][Full Text] [Related]
17. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
18. Etravirine: new drug. Multidrug-resistant HIV: another option.
Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
[TBL] [Abstract][Full Text] [Related]
19. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
